What are the contraindications for sumatriptan?

Sumatriptan Contraindications

Sumatriptan is absolutely contraindicated in patients with ischemic coronary artery disease, history of stroke or TIA, peripheral vascular disease, uncontrolled hypertension, severe hepatic impairment, and within 24 hours of ergotamine-containing medications or other triptans. 1

Absolute Cardiovascular Contraindications

The FDA label explicitly prohibits sumatriptan use in:

• Ischemic coronary artery disease (angina pectoris, prior myocardial infarction, or documented silent ischemia) 1
• Coronary artery vasospasm, including Prinzmetal's angina 1
• Wolff-Parkinson-White syndrome or arrhythmias with other cardiac accessory conduction pathway disorders 1
• Peripheral vascular disease 1
• Ischemic bowel disease 1

Recent evidence from a 2024 Danish nationwide study demonstrates that triptan initiation was associated with 3.2-fold increased odds of ischemic stroke and 3.3-fold increased odds of myocardial infarction, though absolute risk remained very low (0.003-0.008% of initiators) 2. Case patients were typically around 60 years old with high-risk cardiovascular profiles.

Cerebrovascular Contraindications

• History of stroke or transient ischemic attack (TIA) 1
• History of hemiplegic or basilar migraine (these patients have higher stroke risk) 1

Hypertension

• Uncontrolled hypertension is an absolute contraindication 1
• Sumatriptan can cause significant blood pressure elevation, including hypertensive crisis with acute organ impairment 1

Hepatic Impairment

• Severe hepatic impairment is a contraindication 1
• Mild to moderate hepatic impairment requires dose adjustment but is not contraindicated

Drug-Drug Interaction Contraindications

Recent use (within 24 hours) of:

• Ergotamine-containing medications 1
• Ergot-type medications (dihydroergotamine, methysergide) 1
• Another 5-HT1 agonist (any other triptan) 1

MAO-A inhibitors:

• Concurrent administration is contraindicated 1
• Recent use (within 2 weeks) is contraindicated 1

Hypersensitivity

• Known hypersensitivity to sumatriptan (angioedema and anaphylaxis have been reported) 1

Important Clinical Caveats

Serotonin Syndrome Risk

While not an absolute contraindication, concurrent use with SSRIs, SNRIs, TCAs, or MAO inhibitors increases serotonin syndrome risk 1. The 1998 literature review found only 16 cases of serotonin syndrome-like symptoms with SSRIs and 2 with lithium, with most being mild-to-moderate and self-limited 3. However, use caution and monitor closely when combining sumatriptan with serotonergic medications 4.

Cardiovascular Risk Assessment

For triptan-naive patients with multiple cardiovascular risk factors (increased age, diabetes, hypertension, smoking, obesity, strong family history of CAD), perform cardiovascular evaluation before prescribing 1. Consider administering the first dose in a medically supervised setting with immediate post-dose ECG 1.

Special Populations

The 2025 ACP guidelines note that recommendations apply to nonpregnant and nonlactating adults 5. The 2021 Nature Reviews guideline states triptans should be used only under strict specialist supervision during pregnancy, with most safety data limited to sumatriptan from post-marketing surveillance 6.

Medication Overuse Headache

While not a contraindication, be aware that triptan use ≥10 days per month can lead to medication overuse headache 5, 1.

Real-World Prescribing Patterns

A 2022 US study found that 13.9% of patients prescribed triptans had at least one contraindication, with cardiac arrhythmia (8.4%), cerebrovascular disease (3.7%), and coronary artery disease (2.6%) being most common 7. This highlights the importance of careful screening before prescribing.